A clinical study of Yigu capsule in treating postmenopausal osteoporosis
Back to article page
OriginalPaper|Updated:2021-08-27
|
A clinical study of Yigu capsule in treating postmenopausal osteoporosis
A clinical study of Yigu capsule in treating postmenopausal osteoporosis
中国结合医学杂志(英文版)2005年11卷第2期 页码:97-103
Affiliations:
1. The First Affiliated Hospital of Jinan University,Guangzhou
2. Xiyuan Hospital, China Academy of Traditional Chinese Medicine,China
Author bio:
Funds:
Supported by the Natural Science Foundation of Guangdong Province (No. 990475), the Post-doctoral Programs Funds of China(No. 1999-26), the Funds of TCM in Guangdong Province (No. 99580)
Rong-hua, Z., Ke-ji, C., Da-xiang, L. et al. A clinical study of Yigu capsule in treating postmenopausal osteoporosis., Chin. J. Integr. Med. 11, 97–103 (2005). https://doi.org/10.1007/BF02836464
Zhang Rong-hua, Chen Ke-ji, Lu Da-xiang, et al. A clinical study of Yigu capsule in treating postmenopausal osteoporosis[J]. Chinese Journal of Integrative Medicine, 2005,11(2):97-103.
Rong-hua, Z., Ke-ji, C., Da-xiang, L. et al. A clinical study of Yigu capsule in treating postmenopausal osteoporosis., Chin. J. Integr. Med. 11, 97–103 (2005). https://doi.org/10.1007/BF02836464DOI:
Zhang Rong-hua, Chen Ke-ji, Lu Da-xiang, et al. A clinical study of Yigu capsule in treating postmenopausal osteoporosis[J]. Chinese Journal of Integrative Medicine, 2005,11(2):97-103. DOI: 10.1007/BF02836464.
A clinical study of Yigu capsule in treating postmenopausal osteoporosis
摘要
Objective: To observe the efficacy and safety of Yigu capsule (YGC)
a Chinese herbal compound preparation
in treating postmenopausal osteoporosis (PMO) and to explore its possible mechanism.Methods: The clinical study was conducted in a prospective
randomized
double blinded method lasting for 6 months with placebo and positive control. Two hundred and ten PMO patients with confirmed diagnosis were assigned into the YGC group
the calciferol group and the placebo group. Besides being administered element calcium
they were treated with YGC
calciferol capsule and placebo capsule respectively. And such symptoms as newly found fracture and ostealgia
bone mineral density (BMD) of the 2nd–4th lumbar vertebrae (L2–4) and upper femur
blood and urinary indexes for bone metabolism
sex hormone level and adverse reaction that occurred in patients were observed.Results: In the YGC group
the total effective rate was 95. 50%
with no new occurrence of fractures
which was significantly better than that in the other two groups (P<0.05). Moreover
in the YGC group
the increase rate of BMD was 9.83% in L2–4
4.09% in femoral neck
4.60% in Wards triangle
3.00% in greater trochanter
which was also better than that in the placebo group (P<0.05
P<0.01). As compared with the placebo group
levels in the YGC group of urinary oxyproline hydroxyproline/creatinine
urinary calcium/creatinine were significantly lower
serum and bone alkaline phosphatase
osteocalcin
estradiol and estradiol/testosterone were significantly higher
but no difference was shown in the comparison of testosterone level. In the observation period
no abnormality in blood or urine routine
liver or renal function was found. Only mild
transient gastro-intestinal response occurred in individual patients
but it did not affect the treatment.Conclusion: YGC could treat PMO effectively
as it could obviously increase the BMD of lumbar vertebrae and coxafemoral bone
elevate the alleviating rate of ostealgia and incessant motion time
yet causing no newly found compressive fracture of vertebrae
or and any related adverse reaction. YGC could not only promote the formation
but also inhibit the absorption of bone as well as increase the sex hormone level. Therefore
it is a pure Chinese herbal compound preparation worthy of further research and development.
Abstract
Objective: To observe the efficacy and safety of Yigu capsule (YGC)
a Chinese herbal compound preparation
in treating postmenopausal osteoporosis (PMO) and to explore its possible mechanism.Methods: The clinical study was conducted in a prospective
randomized
double blinded method lasting for 6 months with placebo and positive control. Two hundred and ten PMO patients with confirmed diagnosis were assigned into the YGC group
the calciferol group and the placebo group. Besides being administered element calcium
they were treated with YGC
calciferol capsule and placebo capsule respectively. And such symptoms as newly found fracture and ostealgia
bone mineral density (BMD) of the 2nd–4th lumbar vertebrae (L2–4) and upper femur
blood and urinary indexes for bone metabolism
sex hormone level and adverse reaction that occurred in patients were observed.Results: In the YGC group
the total effective rate was 95. 50%
with no new occurrence of fractures
which was significantly better than that in the other two groups (P<0.05). Moreover
in the YGC group
the increase rate of BMD was 9.83% in L2–4
4.09% in femoral neck
4.60% in Wards triangle
3.00% in greater trochanter
which was also better than that in the placebo group (P<0.05
P<0.01). As compared with the placebo group
levels in the YGC group of urinary oxyproline hydroxyproline/creatinine
urinary calcium/creatinine were significantly lower
serum and bone alkaline phosphatase
osteocalcin
estradiol and estradiol/testosterone were significantly higher
but no difference was shown in the comparison of testosterone level. In the observation period
no abnormality in blood or urine routine
liver or renal function was found. Only mild
transient gastro-intestinal response occurred in individual patients
but it did not affect the treatment.Conclusion: YGC could treat PMO effectively
as it could obviously increase the BMD of lumbar vertebrae and coxafemoral bone
elevate the alleviating rate of ostealgia and incessant motion time
yet causing no newly found compressive fracture of vertebrae
or and any related adverse reaction. YGC could not only promote the formation
but also inhibit the absorption of bone as well as increase the sex hormone level. Therefore
it is a pure Chinese herbal compound preparation worthy of further research and development.
关键词
postmenopausal osteoporosistreatmentYigu capsule
Keywords
postmenopausal osteoporosistreatmentYigu capsule
references
Liu ZH, Pan ZA, Liu JP, et al. Review and diagnostic Standard of primary osteoporosis. In: Liu Zhong-hou, editor. Osteoporosis. Beijing: Science Press, 1998 142–161.
Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288(7): 872–881.
Zhang RH. Osteoporosis and its prevention and treatment. J Jinan Univ (Medicine Edition) 1999; 20(6): 32–37.
Fei ZY. Newer review on osteoporosis treated by traditional Chinese medicine. Shanghai J Tradit Chin Med 1999; (6): 47–49
Arlot ME, Sornay-Rendu E, Garnero P, et al. Apparent pre and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res 1997; 12: 683–690.
Takada M, Grampp S, Ouyang X, et al. A new trabecular region of interest for femoral dual X-ray absorption metry: short-term precision, age-related bone loss, and fracture discrimination compared with current femoral regions of interest. J Bone Miner Res 1997; 12: 832–838.
Zhang RH, Chen KJ, Lu DX, et al. Effect of Chinese recipes of replenishing Shen and activating blood circulation on female rats with osteoporosis induced by ovariectomy. Chin J Integr Tradit West Med 1999; 19(10): 614–616.